Mukund Patel
Chicago (USA): Sewa International has launched a Convalescent Blood Plasma National Registry in the USA for COVID-19 patients, the only 24×7 service that offers a national registry in America.
The Sewa Plasma Registry (www.sewacovidplasma.org) is for both donors and recipients under the Convalescent Plasma Therapy program with live phone andsocial media support.
“Our mission is to bring together matching blood donors and COVID-19 patients
seeking the plasma, in-time, and save lives,” said Sewa International President Prof. Sree Sreenath.
Replies to some relevant queries:
Question: What is the Convalescent Covid-19 Plasma Therapy?
Answer: It is an FDA-regulated investigational therapy where plasma is collected from eligible donors and used as a therapy for a restricted class of recipient patients, both of whom have compatible blood type.
Q: Who can be a plasma donor?
A: The donor may be a male or a non-pregnant female, with no prior history of Hepatitis B, Hepatitis C, HIV, or intravenous drug use. S/he can be a COVID-19 survivor with either complete resolution of symptoms at least 28 days prior to donation OR complete resolution of symptoms at least 14 days prior to donation, and negative results for COVID-19 either from one or more nasopharyngeal swab specimens or by molecular diagnostic test from blood.
Q: Who can be a plasma recipient?
A: The recipient is a COVID-19 patient who is acutely ill with respiratory failure deemed to benefit with this therapy after discussion with his or her physician.
The Sewa’s registry is a mobile phone-enabled, fully-functional, self-registry service with email support that offers both pre-screening and donor-patient matching services. The registry includes status updates and email communication with an automatic status change intimation.
Run by a dedicated team of Sewa volunteers, the services adhere to HIPPA medical data protection laws, and protects the privacy and confidentiality of the registered users (donors and recipients).
“A dedicated group of physicians and technologists designed and developed this registry rapidly because they saw the urgent need for such a service nationwide,” said Prem Pusuloori, Sewa Director of National and International Programs.
Users of the registry can call 302 659 SEWA (7392) or contact via
email: PlasmaSupport@SewaUSA.org.
Its results have been encouraging, and more and more physicians are opting for this treatment for their critically ill COVID-19 patients.
